CombinatoRx shares surge on diabetes data

Shares of CombinatoRx surged 39 percent this morning on the news that its experimental diabetes drug hit its primary endpoint in a mid-stage trial. The combination of bezafibrate and diflunisal produced better data than bezafibrate alone. CRx-401 is described as an insulin sensitizer intended to provide a better therapy to patients without weight gain. Report